ReviewSeminars in perinatology2016
Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant.
Review in Seminars in perinatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Opioid treatment for opioid withdrawal in newborn infants.The Cochrane database of systematic reviews · 2021Pooled it
- Sedatives for opioid withdrawal in newborn infants.The Cochrane database of systematic reviews · 2021Pooled it
- Accelerated Weaning of Opioids to Reduce Pharmacologic Exposure for Neonatal Opioid Withdrawal Syndrome: A Randomized Clinical Trial.The Journal of pediatrics · 2026Trial
- Trial
- Neonatal Abstinence Syndrome Severity Index Predicts 18-Month Neurodevelopmental Outcome in Neonates Randomized to Morphine or Methadone.The Journal of pediatrics · 2020Trial
- Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.JAMA pediatrics · 2018Trial
- Association between NNNS-II profiles and pharmacological treatment in infants with prenatal opioid exposure.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Perinatal morphine exposure induces chromatin and transcriptomic remodeling to alter immune and metabolic function.Frontiers in immunology · 2026Article
- A Roadmap to Improved Quality Outcomes in Neonates Exposed to Illegally Manufactured Fentanyl.Journal of pediatrics. Clinical practice · 2025Article
- Association between NNNS-II Profiles and Pharmacological Treatment in Infants with Prenatal Opioid Exposure.Research square · 2025Article
- Modulation of intestinal TLR4 expression in infants with neonatal opioid withdrawal syndrome.Journal of perinatology : official journal of the California Perinatal Association · 2024Article
- Advances in animal models of prenatal opioid exposure.Trends in neurosciences · 2024Review
- Inpatient Growth in Infants Requiring Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome.International journal of pediatrics · 2024Article
- Neonatal opioid toxicity: opioid withdrawal (abstinence) syndrome with emphasis on pharmacogenomics and respiratory depression.Archives of toxicology · 2023Review
- Neonatal Abstinence Syndrome in Infants with Prenatal Exposure to Methadone versus Buprenorphine.Children (Basel, Switzerland) · 2023Article
- Maternal opioids age-dependently impair neonatal respiratory control networks.Frontiers in physiology · 2023Article
- Article
- Does Maternal Incarceration Impact Infants with Neonatal Abstinence Syndrome?Maternal and child health journal · 2022Article
- Effects of Pharmacologic Treatment for Neonatal Abstinence Syndrome on DNA Methylation and Neurobehavior: A Prospective Cohort Study.The Journal of pediatrics · 2022Article
- Establishing evidence-based pharmacologic treatments for neonatal abstinence syndrome: A retrospective case study.Journal of clinical and translational science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Opioid use in pregnancy has increased dramatically over the past decade. Since prenatal opioid use is associated with numerous obstetrical and neonatal complications, this now has become a major public health problem. In particular, in utero opioid exposure can result in neonatal abstinence syndrome (NAS) which is a serious condition characterized by central nervous system hyperirritability and autonomic nervous system dysfunction. The present review seeks to define current practices regarding the approach to the pregnant mother and neonate with prenatal opiate exposure. Although the cornerstone of prenatal management of opioid dependence is opioid maintenance therapy, the ideal agent has yet to be definitively established. Pharmacologic management of NAS is also highly variable and may include an opioid, barbiturate, and/or α-agonist. Genetic factors appear to be associated with the incidence and severity of NAS. Establishing pharmacogenetic risk factors for the development of NAS has the potential for creating opportunities for "personalized genomic medicine" and novel, individualized therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.